http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
임창열,문상희,김정은,손명희 대한내과학회 1990 대한내과학회지 Vol.38 No.3
Hereditary spherocytosis is an inherited hemolytic anemia characterized by anemia, jaundice and splenomegaly. The disease is common in northern Europeans but relatively rare in Korea. Growth retardation is an unusual complication in patients with hereditary spherocytosis. Recently, we experienced a 16-year-old female patient with hereditary spherocytosis associated with growth retardation. She was 137㎝ tall, weighed 30.5㎏ (for 16-year-old Korean girls, the third percentile value of height is 147.6㎝ and that of weight is 40.86㎏) and had a bone age of less than 13 years.
임창열,Im, Chang-Yeol 대한석유협회 1997 석유와 에너지 Vol.1997 No.10
이 자료는 지난 9월 12일 인터컨티넨탈 호텔에서 열린 에너지협의회 조찬간담회에서 발표된 내용임. <편집자 주>
성인급성 골수성 백혈병에 대한 TAD( 6-Thioguanine, Ara-C, Daunorubicin)복합 화학 요법
임창열,안홍석 의과학연구소 1991 全北醫大論文集 Vol.15 No.2
Sixteen adult patients with acute myelogenous leukemia received TAD induction chemotherapy consisting of 7day courses of 6-thioguanine (100mg/m^2, every 12hours) and ara-C (100mg/m?^2, daily), and 3-day courses of daunorubicin (45mg/m^2, daily). The patients who didn't achieve complete remission after the first course of TAD received an additional course of a modified TAD consisting of 5-day courses of 6-thioguanine and ara-C, and 2-day courses of daunorubicin. Drug doses were identical to those used in the first course of TAD. Patients who achieved complete remission after the first or the second course of TAD received an alternating maintenance chemotherapy with are-C/6-thioguanine and are-C/daunorubicin (maximum eight courses). Twelve patients (75%) achieved complete remission Median remission duration was 13 months and median survival 13 months. Bone marrow was profoundly depressed in most patients after TAD. Other toxicities of TAD were anorexia, nausea, vomiting headache, alopecia, stomatitis, diarrhea, hepatotoxicity and skin disooloration. No substantial cardiac, renal or neurological toxicity was observed. These results indicate that TAD regimen is effective in the treatment of acute myelogenous leukemia.